| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/30/2004 | US20040192719 Peptide deformylase inhibitors |
| 09/30/2004 | US20040192717 Salts of guanidine derivatives and pharmaceutical preparations consisting thereof |
| 09/30/2004 | US20040192716 Mixture with 2-amino-1,3-propanediol and excipients; synergistic mixture; concurrent administering |
| 09/30/2004 | US20040192715 Methods of administering opioid antagonists and compositions thereof |
| 09/30/2004 | US20040192714 Analogs and prodrugs of buprenorphine |
| 09/30/2004 | US20040192712 Insecticides; for human or veterinary medicine |
| 09/30/2004 | US20040192711 Kinase inhibitor; therapy for leukemia, lymphoma; skin cancer; autoimmune diseases; antiinflammatory agents; sunscreen agents |
| 09/30/2004 | US20040192710 Such as trans-4-amino-3,4-dihydro-2,2-dimethyl-6-cyano-2H-benzopyran; for use as antiarrhythmic agents |
| 09/30/2004 | US20040192708 Sulfonamide substituted xanthine derivatives |
| 09/30/2004 | US20040192707 Compounds and methods for the treatment or prevention of Flavivirus infections |
| 09/30/2004 | US20040192706 Oral administering; sustained release of ocinaplonin |
| 09/30/2004 | US20040192703 Preferentially substituted calcium channel blockers |
| 09/30/2004 | US20040192702 Heteroaryl alkyl piperazine derivatives |
| 09/30/2004 | US20040192701 Phenlypyridine carbonyl piperazine derivative |
| 09/30/2004 | US20040192699 Vision defects |
| 09/30/2004 | US20040192696 Antiproliferative agents; antiinflammatory agents; neurodegradative disease; autoimmune disease; viricides |
| 09/30/2004 | US20040192694 Use of COX-2 inhibitors as gastroprokinetics |
| 09/30/2004 | US20040192693 Antidiabetic agents; arteriosclerosis; cardiovascular disorders; anticholesterol agents; antidepressants; schizophrenia; antilipemic agents |
| 09/30/2004 | US20040192692 compounds of this invention may interact more favourably with the alpha 2 and/or alpha 3 subunit than with the alpha 1 subunit; and/or may interact more favourably with the alpha 5 subunit than with the alpha 1 subunit |
| 09/30/2004 | US20040192691 Analgesics; antiischemic agents; amyotrophic lateral sclerosis; anticonvulsants; antidepressants; local anesthetics; antiarrhythmia agents; neuropathic pain |
| 09/30/2004 | US20040192690 Central nervous system disorders; side effect reduction; antiepileptic agents; analgesics; antiepileptic agents; edema; multiple sclerosis; psychological disorders; schizophrenia; bipolar disorders |
| 09/30/2004 | US20040192689 Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| 09/30/2004 | US20040192687 Dna-pk inhibitors |
| 09/30/2004 | US20040192686 Potentiators of the cytotoxicity of anticancer drugs; antitumor agents |
| 09/30/2004 | US20040192685 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| 09/30/2004 | US20040192683 Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments |
| 09/30/2004 | US20040192682 1,5-Dihydro-pyrazolo[4,3-c]pyridazin-6-one derivatives; glycogen synthase kinase-3 (CSK) inhibitors; nervous system, psychological, and neurodegenerative disorders; diabetes, psychiatry, multiple sclerosis (MS), myocardial infarction, reperfusion/ischemia, alopecia, and stroke |
| 09/30/2004 | US20040192681 N-acylsulfonamide apoptosis promoters |
| 09/30/2004 | US20040192679 Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof |
| 09/30/2004 | US20040192678 Pyrrolo[2,1-c][1,4] benzodiazepines compounds and process thereof |
| 09/30/2004 | US20040192677 Dna binding, antitumour activity |
| 09/30/2004 | US20040192675 Pharmaceutical compositions containing tiotropium salts and antihistamines and their use |
| 09/30/2004 | US20040192674 Cathepsin L inhibitors |
| 09/30/2004 | US20040192673 Obesity, non-insulin-dependent diabetes,strokes, sleep disorders; antiischemic and antiemetic agents |
| 09/30/2004 | US20040192671 Benzo[d]azepine derivatives as 5-ht6 receptor anatagonists |
| 09/30/2004 | US20040192670 For inhibiting bone resorption, treating/preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, aniogenesis, atherosclerosis, arthritis, tumor growth and metastasis |
| 09/30/2004 | US20040192667 Novel pyrazole analogs acting on cannabinoid receptors |
| 09/30/2004 | US20040192666 Nonnucleoside reverse transcriptase inhibitors |
| 09/30/2004 | US20040192665 Mesoporphyrin IX covalently linked to doxorubicin; anticarcinogenic, antiproliferative, and antitumor agents; side effect reduction |
| 09/30/2004 | US20040192663 measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator such as deferiprone; method can include measuring total urinary protein content, blood urea nitrogen, or creatinine |
| 09/30/2004 | US20040192662 Topically administering tazarotene gel and corticoid cream |
| 09/30/2004 | US20040192661 Micronized eplerenone compositions |
| 09/30/2004 | US20040192660 Protocol for improving vision |
| 09/30/2004 | US20040192659 Sodium channel blocker binds SS1 or SS2 site of extracellular region; cyclooxygenase inhibitor; side effect reduction; tetrodotoxin or derivative |
| 09/30/2004 | US20040192656 Methods and compositions for the treatment of human and animal cancers |
| 09/30/2004 | US20040192654 use of nucleoside analogues as an effective treatment for acute or chronic myelogenous leukemia; (-)- beta -L-Dioxolane-Cytidine ( beta -L-oddC); (-)- beta -Dioxolane-5-fluoro-Cytidine (5-FddC) |
| 09/30/2004 | US20040192653 P38 inhibitors and methods of use thereof |
| 09/30/2004 | US20040192652 Pharmaceutical combinations and methods for the treatment of leukemia |
| 09/30/2004 | US20040192649 Skin care compositions containing a sugar amine |
| 09/30/2004 | US20040192648 Peritoneal dialysis solution containing modified icodextrins |
| 09/30/2004 | US20040192647 topically applying an aqueous ophthalmic composition comprising N-acetylcarnosine, a N-acetylcarnosine derivative and a cellulose compound which increases intraocular absorption of N-acetylcarnosine; a hydrophilic hydrogel contact lens and an ocular polymer insert for topical application |
| 09/30/2004 | US20040192645 detecting chitin in mammals; useful for diagnosing disease caused by accumulation of chitin or amyloid plaques such as Alzheimer's disease, spongiform encepalopathies, type II diabetes, atrial amyloidosis; administering the composition to inhibit polymerization of N-acetylglucosamine to chitin |
| 09/30/2004 | US20040192644 DDS compound and method for measurement thereof |
| 09/30/2004 | US20040192642 Prevention of urogenital infections |
| 09/30/2004 | US20040192641 formed from polysaccharides of kelp (PK), an anticancer and increases immunity, and new nanoparticles (NP) and special liposome (SSL), which contained natural anticancer drug; improvement of efficacy of Homoharringtonine (HHT), Curcumol (CUR), Elemene (ELE) and Camptothecin (CPT) by NP and SSL |
| 09/30/2004 | US20040192640 Use of sucralfate for the treatment of cervical erosion |
| 09/30/2004 | US20040192638 Method and composition for prolonging the residence time of drugs in the gut |
| 09/30/2004 | US20040192637 HPMPC [(S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine]; kits; cytotoxicity; inhibition against viral and/or cellular polymerases; treatment of non virus-associated cancers |
| 09/30/2004 | US20040192636 Methods for the treatment and prevention of neurodegenerative conditions |
| 09/30/2004 | US20040192632 comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with the Non-Immunogenic or High Molecular Weight Compound |
| 09/30/2004 | US20040192628 gene expression inhibition of the kinase to prevent neovascularization, treat cancer |
| 09/30/2004 | US20040192624 UDP-glucuronosyltransferases (UGTs), UGT1A1 being a bilirubin-specific isozyme; inducing UGT1A1 isoform expression for treating unconjugated hyperbilirubinemia by administering ritonavir; side effect reduction of AIDS drugs such as indinavir, atazanavir, amphotericin B/cholesteryl sulfate complex |
| 09/30/2004 | US20040192623 Aloe-emodin derivatives and their use in the treatment of neoplasias |
| 09/30/2004 | US20040192622 intimate admixture of azithromycin and a stabilizing amount of an antioxidant; treating a bacterial infection |
| 09/30/2004 | US20040192620 suppressing follicle maturation and ovulation and replacing the endogenous ovarian secretion of 17 beta-estradiol; 1,3,5 (10)-estratrien-3, 15 alpha ,16 alpha ,17 beta -tetrol for example; does not employ co-administration of a luteinizing hormone releasing hormone; less side effects |
| 09/30/2004 | US20040192619 Hepatoprotective agent of plant origin and a process thereof |
| 09/30/2004 | US20040192618 Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use |
| 09/30/2004 | US20040192617 Making gabapentin tannate to treat central nervous system disorders by reacting gabapentin and tannic acid; improves certain organoleptic properties such as taste |
| 09/30/2004 | US20040192616 Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
| 09/30/2004 | US20040192614 kit comprising an osmotic colonic evacuant, and an oral rehydration solution comprising a a glucose containing saccharide and a sodium salt (such as in a popular sports drink); for use such as prior a colonoscopy; optimizing the safety of this procedure |
| 09/30/2004 | US20040192607 Transcriptional regulation of the human beta3-adrenergic receptor gene |
| 09/30/2004 | US20040192606 treating an infection or ischemic wound in a mammal by administering relaxin; treating ischemic ulcer with recombinant human relaxin (H2) for example |
| 09/30/2004 | US20040192598 Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| 09/30/2004 | US20040192588 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 09/30/2004 | US20040192587 Zinc formulations as a prophylactic treatment for the common cold |
| 09/30/2004 | US20040192585 Administering to a patient an amount of IRM(immune respose modifier) compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is administered and at least one day in which the IRM compound is not administered |
| 09/30/2004 | US20040192584 Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor |
| 09/30/2004 | US20040192583 Administering to an obese mammal or a mammal at risk of developing obesity a therapeutically effective amount of a compound having nitrogen containing mono or bicyclic ring capable of inhibiting TGF- beta signaling through a TGF- beta receptor |
| 09/30/2004 | US20040192581 Applying a topical formulations prepared from lysostaphin and lantibiotics such as nisin that are effective in treating dermatological and wound infections without disrupting the balance of non-pathogenic and pathogenic populations of skin flora |
| 09/30/2004 | US20040192579 Administration of the mammal a formulation containing a matrine component and dictamnine in amount effective to deliver daily amount of at least 15 mu mole of a matrine component and at least 0.15 mu mole of dictamnine/kg of body weight to treat cancer |
| 09/30/2004 | US20040192578 High specificity anticancer drug design process |
| 09/30/2004 | US20040192553 Inosine L-Arginine salt and uses thereof |
| 09/30/2004 | US20040191898 Trangenic diploid cell comprising mutation in kinase allele for use in screening modulator for treatment of anxiety, addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures and epilepsy |
| 09/30/2004 | US20040191874 Process for preparation of 9, 11-epoxy steroids and intermediates useful therein |
| 09/30/2004 | US20040191843 Cytotoxic mixture comprising polypeptides for treatment and prevention of cell proliferfative disorders |
| 09/30/2004 | US20040191842 Chemopreventive and therapeutic aspects of polyphenolic compositions and assays |
| 09/30/2004 | US20040191832 Avidin derivatives and uses thereof |
| 09/30/2004 | US20040191803 Preparing animal models and testing compounds for treatment of age related cognitive impairment; gene therapy and alzheimer's disease |
| 09/30/2004 | US20040191800 Comprises nucleotide sequences coding protein which controls thermogenesis in human skeletal muscle and heart for prevention and treatment of obesity, cachexia, cardiovascular and muscular disorders |
| 09/30/2004 | US20040191791 Comprises nucleotide sequences coding sodium voltage gated channels for identifying modulators for treatment of epilepsy; diagnosis of seizure disorders |
| 09/30/2004 | US20040191773 Oligoribonucleotides and ribonucleases for cleaving RNA |
| 09/30/2004 | US20040191756 Transgenic rodent for diagnosing and identifying modulator for treatment and prevention inflammatory disorders |
| 09/30/2004 | US20040191345 New formulations and use thereof |
| 09/30/2004 | US20040191344 Pharmaceutical composition for prophylaxis or treatment of osteoporosis, and method to prepare the same |
| 09/30/2004 | US20040191343 Hepatoprotective pharmaceutical composition comprising a mixture of coumarinolignoids, process for preparation thereof |
| 09/30/2004 | US20040191342 Such as beta-caryophyllene extracted from plant oil |
| 09/30/2004 | US20040191338 Administration of capsaicinoids |
| 09/30/2004 | US20040191334 Use of transhinone derivates as cholinesterase inhibitors in treating related diseases |
| 09/30/2004 | US20040191332 Preserved ophthalmic compositions |
| 09/30/2004 | US20040191331 Superior antidandruff shampoos |